Merck KGaA (MRK, NYSE: MRK) , a leading science and technology company based in Germany, has announced the availability of its ovulation-stimulating treatment Pergoveris in the Guangdong–Hong Kong–Macao Greater Bay Area. The treatment, which combines recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH), has been approved for use in the Sun Yat-sen Memorial Hospital, making it the first assisted reproductive drug in the area under the “Hong Kong Macau Drug and Device Access” policy.
Pergoveris is recognized as the world’s first and only r-hFSH/r-hLH compound preparation that maintains the FSH: LH 2:1 ratio, which is crucial for ovulation stimulation. The treatment is already registered in over 100 countries and regions globally. Clinical studies have demonstrated that Pergoveris can enhance pregnancy outcomes in various patient populations, including those with hypogonadotropic hypogonadism (HH), low/slow response, low prognosis, LH transient iatrogenic deficiency due to GnRH antagonists or agonists, and in older populations.
The introduction of Pergoveris in the Greater Bay Area is a significant step forward in advancing reproductive healthcare options, offering a new dimension in treatment for infertility and supporting the growing demand for advanced reproductive technologies in the region.- Flcube.com
